Using mouse models to investigate the biological and physiological consequences of defects in the Fanconi anaemia/breast cancer DNA repair signalling pathway

Journal of Pathology

Volumn 224, Issue 3, 2011, Pages 301-305

  Tischkowitz, Marc ^a,b   Winqvist, Robert ^c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

breast cancer; Fanconi anaemia; knockout; mouse model; PALB2

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; FANCONI ANEMIA PROTEIN;

ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CARCINOGENESIS; DNA DAMAGE; DNA REPAIR; FANCONI ANEMIA; GENE MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DNA REPAIR; DNA, NEOPLASM; FANCONI ANEMIA; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASTIC SYNDROMES, HEREDITARY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 79958221787     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2903     Document Type: Article

References (39)

1. Bouwman P, Drost R, Klijn C, et al., Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression. J Pathol 2011; 224: 10-21.
2. Xia B, Sheng Q, Nakanishi K, et al., Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006; 22: 719-729.
3. Tischkowitz M, Xia B,. PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res 2010; 70: 7353-7359.
4. Sy SM, Huen MS, Chen J,. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA 2009; 106: 7155-7160.
5. Zhang F, Fan Q, Ren K, et al., PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res 2009; 7: 1110-1118.
6. Auerbach AD,. Fanconi anemia and its diagnosis. Mutat Res 2009; 668: 4-10.
7. Rosenberg PS, Greene MH, Alter BP,. Cancer incidence in persons with Fanconi's anemia. Blood 2003; 101: 822-825.
8. de Winter JP, Joenje H,. The genetic and molecular basis of Fanconi anemia. Mutat Res 2009; 668: 11-19.
9. Rego MA, Kolling FWt, Howlett NG,. The Fanconi anemia protein interaction network: casting a wide net. Mutat Res 2009; 668: 27-41.
10. Vaz F, Hanenberg H, Schuster B, et al., Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010; 42: 406-409.
11. Ciccia A, Elledge SJ,. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40: 179-204.
12. Kee Y, D'Andrea AD,. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev 2010; 24: 1680-1694.
13. Alter BP, Rosenberg PS, Brody LC,. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet 2007; 44: 1-9. (Pubitemid 46142832)
14. Reid S, Schindler D, Hanenberg H, et al., Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007; 39: 162-164. (Pubitemid 46184345)
15. Carreau M,. Not-so-novel phenotypes in the Fanconi anemia group D2 mouse model. Blood 2004; 103: 2430. (Pubitemid 38326272)
16. Agoulnik AI, Lu B, Zhu Q, et al., A novel gene, Pog, is necessary for primordial germ cell proliferation in the mouse and underlies the germ cell deficient mutation, gcd. Hum Mol Genet 2002; 11: 3047-3053. (Pubitemid 35414818)
17. Futaki M, Yamashita T, Yagasaki H, et al., The IVS4 + 4 A to T mutation of the Fanconi anemia gene FANCC is not associated with a severe phenotype in Japanese patients. Blood 2000; 95: 1493-1498. (Pubitemid 30099866)
18. Crossan GP, van der Weyden L, Rosado IV, et al., Disruption of mouse Slx4, a regulator of structure-specific nucleases, phenocopies Fanconi anemia. Nat Genet 2011; 43: 147-152.
19. Pulliam-Leath AC, Ciccone SL, Nalepa G, et al., Genetic disruption of both Fancc and Fancg in mice recapitulates the hematopoietic manifestations of Fanconi anemia. Blood 2010; 116: 2915-2920.
20. Wong JC, Alon N, McKerlie C, et al., Targeted disruption of exons 1 to 6 of the Fanconi anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia. Hum Mol Genet 2003; 12: 2063-2076. (Pubitemid 37038815)
21. Houghtaling S, Timmers C, Noll M, et al., Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev 2003; 17: 2021-2035. (Pubitemid 36999328)
22. Rantakari P, Nikkilä J, Jokela H, et al., Inactivation of Palb2 gene leads to mesoderm differentiation defect and early embryonic lethality in mice. Hum Mol Genet 2010; 19: 3021-3029.
23. Casadei S, Norquist BM, Walsh T, et al., Contribution to familial breast cancer of inherited mutations in the BRCA2-interacting protein PALB2. Cancer Res 2011; 71: 2222-2229.
24. Garcia MJ, Fernandez V, Osorio A, et al., Analysis of FANCB and FANCN/PALB2 Fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat 2009; 113: 545-551.
25. Tischkowitz M, Xia B, Sabbaghian N, et al., Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA 2007; 104: 6788-6793. (Pubitemid 47175579)
26. Erkko H, Xia B, Nikkilä J, et al., A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007; 446: 316-319. (Pubitemid 46426155)
27. Jones S, Hruban RH, Kamiyama M, et al., Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324: 217.
28. Potapova A, Hoffman AM, Godwin AK, et al., Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res 2008; 68: 998-1002. (Pubitemid 351272217)
29. Warren M, Lord CJ, Masabanda J, et al., Phenotypic effects of heterozygosity for a BRCA2 mutation. Hum Mol Genet 2003; 12: 2645-2656. (Pubitemid 37304687)
30. Kote-Jarai Z, Matthews L, Osorio A, et al., Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage. Clin Cancer Res 2006; 12: 3896-3901. (Pubitemid 44078072)
31. Arnold K, Kim MK, Frerk K, et al., Lower level of BRCA2 protein in heterozygous mutation carriers is correlated with an increase in DNA double strand breaks and an impaired DSB repair. Cancer Lett 2006; 243: 90-100. (Pubitemid 44485323)
32. Cheng NC, van de Vrugt HJ, van der Valk MA, et al., Mice with a targeted disruption of the Fanconi anemia homolog Fanca. Hum Mol Genet 2000; 9: 1805-1811. (Pubitemid 30608614)
33. Chen M, Tomkins DJ, Auerbach W, et al., Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia. Nat Genet 1996; 12: 448-451. (Pubitemid 26105940)
34. Whitney MA, Royle G, Low MJ, et al., Germ cell defects and hematopoietic hypersensitivity to γ-interferon in mice with a targeted disruption of the Fanconi anemia C gene. Blood 1996; 88: 49-58. (Pubitemid 26230670)
35. Sharan SK, Morimatsu M, Albrecht U, et al., Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997; 386: 804-810. (Pubitemid 27181248)
36. Yang Y, Kuang Y, Montes De Oca R, et al., Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9. Blood 2001; 98: 3435-3440.
37. Koomen M, Cheng NC, van de Vrugt HJ, et al., Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9-null mice. Hum Mol Genet 2002; 11: 273-281. (Pubitemid 34173356)
38. Bakker ST, van de Vrugt HJ, Rooimans MA, et al., Fancm-deficient mice reveal unique features of Fanconi anemia complementation group M. Hum Mol Genet 2009; 18: 3484-3495.
39. Noll M, Battaile KP, Bateman R, et al., Fanconi anemia group A and C double-mutant mice: functional evidence for a multi-protein Fanconi anemia complex. Exp Hematol 2002; 30: 679-688. (Pubitemid 34831687)